Our study demonstrates that KS-40070, a selective DYRK1B inhibitor, has significant therapeutic potential for treating metabolic disorders such as obesity, type 2 diabetes, and fatty liver disease. Here, DYRK1B is linked to type 2 diabetes mellitus.